qiagen s “4p” strategy in mdx · 2013-04-26 · overall market size ca. 70 busd growth varies...

Sample & Assay Technologies- 1 -QIAGEN Analyst and Investor Day, February 11, 2010

QIAGEN’s“4P”

Strategy

In MDx

Analyst and Investor Day 2010Peer M. Schatz

Chief Executive Officer

New York, February 11th, 2010


The Future - Our Vision

Molecular information is going to be important and a mega trend.

To understand the molecular basis of life, the global research community invests every year more than US$ 120.000.000.000 .

The result: correlation between genotypes and phenotypes.

Molecular information will be used to make decisions in everyday life.

What makes humans different? And what is unique?

How can we identify criminals?

How can we stop cancer?

How can we improve the quality of food?

What is the difference between healthy and sick?

How can we develop better drugs?

We are just at the beginning: Molecular revolution has just started!


QIAGEN Takes the Lead ...

… by leveraging the continuum from Research to Routine Testing

Early access to new technologiesSample technologiesAssay technologiesPlatforms

Early access to new and novel contentPathogensBiomarker

Access to early adopter and key opinion leader inPreventionProfilingPersonalized HealthcarePoint of Need

.... in Providing Sample & Assay Technologies to AccessMolecular Information to Improve Decision Making Processes.

.... in Providing Sample & Assay Technologies to AccessMolecular Information to Improve Decision Making Processes.


SystemsBiology

Academia

MolecularDiagnostics

Applied Testing

Pharma

WorkflowStandardization

RNA

Protein

Market-segments

DNA

Sample & Assay

Technologies

QIAGEN Strategy 2004 -

Recap

QIAGEN2004


Building Leadership in 4 Ps of MDx Strategy

Headline Product Platform Expansion

PreventionHPV QIAensemble

Further screening applications Cancer Dx, Infectious diseases, Vaginosis, Trichomonas,GBS, CT/GC, colon ca, etc.

Profilingartus portfolio QIAsymphony

HIV, HBV, HCV, CMV, EBV, VZV, BKV, .......Cardiovascular, CNS, Autoimmune

Personalized HealthcareKRAS QIAsymphony

BRAF, EGFR, EGFRvIII, PI3K, NRAS, ABL, ...

Point of NeedTBA ESE Tube Scanner

Open source platform


2009

2008

2007

2006

2005

2004

Prevention Profiling PersonalizedHealthcare

Point of Need

Building Leadership in MDx Externally by Strategic Acquisitions

HDATechnology

HDATechnology

Sample technologies& PCR reagents

http://www.artus-biotech2.com/

http://www.sabiosciences.com/home.php

http://gene.genaco.com/index.html

http://gene.genaco.com/index.html


Building Leadership in MDx Internally by Content and Assay Technology Diversification

Sample technologies& PCR reagents

2015 -

2010

Further screening applications Cancer Dx, Infectious diseases, Vaginosis, Trichomonas,GBS

HIV, HBV, HCV, CMV, EBV, VZV, BKV, .......Profiling for Autoimmune diseases, CNS, oncologyCardiovascular, others

CDx for Autoimmune diseases, CNS, oncologyCardiovascular, others

Meningitis

careHPV, Influenza, HAI

2009CT/GCdigene HPV eHC Testdigene HPV eHC 16 18/45 Test

Influenza, H1N1, CMV, Borelia, Enterovirus, M. pneumonia, M. tuberculosis, West Nile, Parvo 19, SARS,

Industry leading portfolio incl.:•

KRAS, EGFR, BRAF, PI3K•

Pathogen, Genotyping,

Headline product: digene HV2 test

L. pneumophila, CMV, HSV, HZV, and many, many more

KRAS

Multiplex portfolioResPlex I, IIAvian Flu, HAI,MVPlex

Headline products:artus RT-PCR assay s> 80 assays built out to > 120 assays today

2004


Point of Need


Building Leadership in MDx ... And Platforms Addressing all Needs in Molecular Diagnostics

2015 -

2010

2009

2004


Point of Need


QIAGEN’s 4 “P” Framework in MDx

LABORATORY BASED TESTING POINT OF NEED

Prevention

Asymptomatic patientsGoal: Early detection

Profiling

Symptomatic patientsGoal: Confirm

PersonalizedHealthcarePre-diagnosed patientsGoal: Guide therapy

Rapid turnaround neededNo laboratory reachableGoal: fast result, on spot

Assay Technologies

Narrow portfolioHigh volume/<$20/assay

Broad portfolioHigh value,low volume

Growing portfolioHigh value,low volume

Emerging segmentInstrument <$2k, Assays: $3-30

Examples• HPV• Chlamydia/NG• 6 assays in in total

an more to come

Examples• CMV• EBV• HBV• HIV• HCV• Influenza

Examples• KRAS• EGFR• BRAF• PI3K• Pathogen

Genotyping

Examples• careHPV• HAI• Influenza

Instruments

High throughputContinuous load

Random accessContinuous load

Random accessContinuous load

Portable test systemsRapid turn around < 2hrs

QIAensemble QIAsymphony QIAsymphony TBA

Assay Design Fast, typically isothermal amplification or no amp

PCR Pyrosequencing

PCR Pyrosequencing

Isothermal amplification


Revenue Development Per Customer Group in MDx

CAGR 2010-2015 ~15%

2005 2010E 2015E

PreventionProfilingPersonalized HealthcarePoint of Need


Growth Drivers in Molecular Diagnostics Prevention

MarketScreening market: High volumes / low prices ($8-20)Strong growth – approx. 15% -20%Huge untapped potential market potential

PortfolioToday: digene HPV screening testTomorrow: digene HPV eHC screening test

digene HPV eHC 16/18/45 genotyping testamplified assays: CT/GC, Trichomonas, Vaginosis, Group B Strep plusadditional opportunities in e.g. cancer screening and others

PlatformUltra high throughput: QIAensemble SP + QIAensemble 2000High – mid throughput: QIAensemble SP + QIAensemble 400/3000+Low – mid throughput: QIAsymphony + QIAensemble 400/3000+

Highlights 2010Launch QIAensemble in EuropeData on clinical trials of next generation HPV tests and platformsApproximately 40,000 patient involved

2005 2010E 2015E



Growth Drivers in Molecular Diagnostics Profiling

MarketIncreasing molecular infectious disease testing Growing with approx. 10% -15%Ongoing requirement for rapid development of new tests(e.g. SARS, H1N5, H1N1)

Complete portfolio based on different assay technologiesartus RT PCR assay portfolio > 120 different assays15 FDA (PMA approved or 510k cleared) products

>100 CE-marked products, 10 SFDA approved assays Multiplexing assaysPyrosequencing assays

PlatformsQIAsymphony SP + ASQIAsymphony RGQQIAsymphony PyrQIAsymphony Plus

Highlights 2010Launch QIAsymphony RGQ in EuropeNumerous tests launchesStart of clinical trials (FDA) CMV, EBV, ResPlex II, artus InfluenzaCE labeling of HSV, HHV, ResPlex II. VZV, BK expected

2005 2010E 2015E



Growth Drivers in Molecular Diagnostics Personalized Healthcare

MarketMarket driven by need of drug efficiency and patient safetyGrowing with > 20%> 15 partnerships with pharma for companion diagnosticsincl. Amgen, Pfizer, BMS, Astra Zeneca, Merck, Lilly, ImClone, BI, ....Biomarker research provides future targets

PortfolioKRAS, BRAF, EGFR, EGFR cIII, PI3K, ...

Pathogen genotyping

PlatformQIAsymphony SP + ASQIAsymphony RGQQIAsymphony PyrQIAsymphony Plus

Highlights 2010Submission KRAS test with AmgenNine further test under development

2005 2010E 2015E


Your

Nam

e H

ere


Growth Drivers in Molecular Diagnostics Point of Need

MarketRapid turnaroundNo laboratoryAcute care (ER, mobile)Huge market growth from very small basis

PortfoliocareHPVInfluenza Bacterial testsHAI

PlatformHandheld based on fluorescence analysis /(ESE)

QIAcare

2005 2010E 2015E


Highlights 2010Launch careHPV

First PON assays for applied testing on ESE platform


Strategic corridor 2004

Expanding the Strategic Corridor

Strategic corridor 2009


QIAGEN’s

Extended Strategic Territory

Molecular information processSample

prep. TestingSampleprep. Testing Use of

informationSample

prep. TestingResult generationSample

preparation TestingSamplecollection

Result interpretation

Mar

ket s

egm

ents

Appliedtesting

Pharma

MolecularDiagnostic

Academia

Consumer (Point-of-care, Patient)

IT(Software)

Consumables& Instruments

SupportingServices

Content(Tests)

Workflow /Value Chain

Market-segments

Analytes

QIAGEN's

Strategic Territory: Sample & Assay Technologies


Expansion of product portfolio

Seven Growth Dimensions

Vertical integration

Transfer of core competence

Products

ServicesNew business models

Additional potential growth dimensions

Increased market penetration$$

Geographical expansion

Today's primary growth dimensions

Addressing new segments

Molecular information processSampleprep. TestingSample

prep. Testing Use of information

Sampleprep. TestingResult generation

Sample preparation Testing

Samplecollection

Result interpretation

Mar

ket s

egm

ents

Appliedtesting

Pharma

MolecularDiagnostic

Academia

Consumer (Point-of-care, Patient)

IT(Software)

Consumables& Instruments ServicesContent

(Tests)

Products

Services

$$

Workflow /Value Chain

Market-segments

Focus 2010 -

2015


QIAGEN‘s Relevant Market: 70 B$ plus

Source: Market information

Kalorama, The Worldwide Market for In Vitro Diagnostic Tests, 2006

Overall Dx

and Testing market(incl. Dx

services)

MDx(1) 5 B$

70 B$(1)

120 B$

Incl. IVD and AT product markets

Life Sciences30 B$

QIAGEN's

Strategic Territory: Sample & Assay Technologies


Executive Summary

.

QIAGEN focusing on „Sample and Assay Technologies“

.

Markets for „Sample and Assay Technologies“ are large and attractive

Overall market size ca. 70 BUSD

Growth varies depending on segments between 5 and 20%

Mega trend „molecular information“ basis for sustainable growth

Prevention assays transformational, e.g. in cancer

Personalized healthcare will be major value driver

QIAGEN with very attractive starting position

.

Primary growth drivers in the future should be

Increased market penetration

Expansion of product portfolio in Sample & Assay technologies

Geographical expansion into high-growth markets

New segments where Sample & Assay Technologies are key


HBV Hepatitis B VirusHCV Hepatitis C VirusHHV Human HerpesvirusHIV Human Immundeficiency Virus HPV Human Papilloma VirusHSV Herpes Simplex VirusHV2 Haplogroup HV 2HZV Herpes ZosterIncl. IncludingIVD In Vitro DiagnosticK KiloKRAS Kirsten Rat Sarcoma MDx Molecular DiagnosticsNRAS Neuroblastoma Rat Sarcoma PCR Polymerase Chain ReactionPI3K Phosphoinositide 3-KinasesPMA Premarket approvalPON Point of NeedRNA Ribonucleic acidRT-PCR Real-time Polymerase Chain ReactionSARS Severe Acute Respiratory SyndromeSFDA State Food and Drug AdministrationTBA To Be AnnouncedVZV Varicella Zoster Virus

ABL Abelson Murine Leukemia Amp AmplificationApprox. ApproximatelyAT Applied TestingB BillionBKV Human Polyomavirus 1BRAF B - Rapidly Growing FibrosarcomaCAGR Compound Annual Growth Rate CE European Conformance MarkNG Neisseria GonorrhoeaeCMV Cytomegalie-VirusCNS Central Nervous SystemColon Ca Colon CancerCT Chlamydia TrachomatisDNA Deoxyribonucleic AcidDx DiagnosticsE EstimatedEBV Epstein-Barr VirusE.g. Exempli GratiaEGFR Epidermal Growth Factor ReceptorER Emergency RoomGBS Group B StreptococcusH1N1 Influenza A Virus Subtype H1N1H1N5 Influenza A Virus Subtype H1N5HAI Hospital Acquired Infections

List of Abbreviations


.

Thank you !

qiagen s “4p” strategy in mdx · 2013-04-26 · overall market size ca. 70 busd growth varies...

Documents